Table 6.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1996 to 2005

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 51 79 88 139 134 167 180 158 182 198
Tx with Antirejection Treatments 20 22 21 30 28 20 36 29 33 31
Antibodies Any in Category 60.0% 68.2% 52.4% 90.0% 92.9% 65.0% 63.9% 79.3% 57.6% 51.6%
Atgam/NRATG/NRATS 45.0% 18.2% 9.5% 0.0% 0.0% 5.0% 0.0% 0.0% 3.0% 0.0%
OKT3 45.0% 59.1% 47.6% 73.3% 57.1% 30.0% 41.7% 27.6% 21.2% 25.8%
Thymoglobulin 0.0% 0.0% 9.5% 40.0% 57.1% 40.0% 33.3% 58.6% 27.3% 35.5%
Zenapax 0.0% 0.0% 0.0% 13.3% 3.6% 5.0% 2.8% 10.3% 3.0% 0.0%
Simulect 0.0% 0.0% 0.0% 3.3% 3.6% 5.0% 0.0% 0.0% 0.0% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 11.1% 37.9% 27.3% 3.2%
Corticosteroids Any in Category 90.0% 63.6% 71.4% 73.3% 78.6% 90.0% 83.3% 79.3% 84.8% 83.9%
Steroids 90.0% 63.6% 71.4% 73.3% 78.6% 90.0% 83.3% 79.3% 84.8% 83.9%
Antimetabolites Any in Category 0.0% 4.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 4.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.